Evaluating colorectal cancer screening strategies (immunological test vs biochemical test) in Catalonia, Spain 2008-2010;Evaluación de dos estrategias de cribado de cáncer colorrectal: Test inmunológico versustest Bioquímico. Cataluña, 2008-2010

Revista Espanola de Salud Publica

Volumn 85, Issue 6, 2011, Pages 593-602

  Martínez, Montse García ^a,b,e   Rodríguez, Gemma Binefa ^a,b   Díaz, Núria Milà ^a,b   Moranta, Francisco Rodríguez ^a,b   Diego, Núria Gonzalo ^b   Sńnchez, Carmen Muñoz ^b   Piñol, Josep Alfons Espinàs ^a,c,d   Andrés, Josep Maria Borràs ^a,c,d   Aguado, Víctor Moreno ^a,b,d  

^a BELLVITGE BIOMEDICAL RESEARCH INSTITUTE IDIBELL   (Spain)

^b HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^c Generalitat de Cataluña   (Spain)

^d UNIVERSITY OF BARCELONA   (Spain)

^e CATALAN INSTITUTE OF ONCOLOGY   (Spain)

Author keywords

Colorectal neoplasms; Outcome and process assessment; Screening; Secondary prevention

Indexed keywords

EID: 84860269416     PISSN: 11355727     EISSN: 16969820     Source Type: Journal    
DOI: 10.1590/s1135-57272011000600008     Document Type: Review

References (30)

1. Lopez-Abente G, Ardanaz E, Torrella-Ramos A, Mateos A, Delgado-Sanz C, Chirlaque MD. Changes in colorectal cancer incidence and mortality trends in Spain. Ann Oncol. 2010;21 (supl.3):iii76-iii82.
2. Borràs JM, Pareja L, Peris M, Espinàs JA. Análisis de la incidencia, la supervivencia y la mortlidad según las principales localizaciones tumorales, 1985-2019: cáncer colorrectal. Med Clin. 2008;131:58-62.
3. Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer. 2010;46:765-81.
4. Recommendations on cancer screening in the European union. Advisory Committee on Cancer Prevention. Eur J Cancer. 2000;36:1473-8.
5. Council Recommendation of 2 December 2003 on cancer screening. Official J Eur Union 2003; 2003/878/EC: 34-8.
6. Ministerio de Sanidad y Política social. Estrategia en cáncer del Sistema Nacional de Salud. Actualización aprobada por el Consejo Interterritorial del Sistema Nacional de Salud, el 22 de octubre de 2009. Madrid: Ministerio de Sanidad y Política Social; 2010.
7. Towler B, Irwig L, Glasziou P, Kewenter J, Weller D, Silagy C. A systematic review of the effects of screening for colorectal cancer using the faecal occult blood test, hemoccult. BMJ. 1998;317:559-65. (Pubitemid 28395924)
8. Hewitson P, Glasziou P, Watson E, Towler B, Irwig L. Cochrane systematic review of colorectal cancer screening using the fecal occult blood test (hemoccult): an update. Am J Gastroenterol. 2008;103:1541-9. (Pubitemid 351813919)
9. Quintero E, Andreu M, Lanas A, Piqué JM. Estrategias para la detección precoz del cáncer colorrectal. En: Bandrés F, Castells A, Morillas JD (coord). La prevención del cáncer colorrectal en España. Alianza para la prevención del cáncer de colon. Madrid: Fundación Tejerina;2009.
10. European guidelines for quality assurance in colorectal cancer screening and diagnosis. Segnan N, Patnick J, von Karsa L (eds). European guidelines for quality assurance in colorectal cancer screening and diagnosis -First edition. Luxembourg: European Commission, Publications Office of the European Union;2010.
11. Smith A, Young GP, Cole SR, Bampton P. Comparison of a brush-sampling fecal immunochemical test for haemoglobin with a sensitive guaiac-based fecal occult blood test in detection of colorectal neoplasia. Cancer. 2006;107:2152-9. (Pubitemid 44665648)
12. Allison JE, Sakoda LC, Levin TR, Tucker JP, Tekawa IS, Cuff T, et al. Screening for colorectal neoplasms with new fecal occult blood tests: Update on performance characteristics. J Natl Cancer Inst. 2007;99:1462-70.
13. Guittet L, Bouvier V, Mariotte N, Vallee JP, Arsène D, Boutreux S, et al. Comparison of guaiac-based and immunochemical fecal occult blood test in screening for colo-rectal cancer in general average-risk population. Gut. 2007;56:210-4.
14. Fattah AS, Nakama H, Kamijo N, Fujimori K, Zhang B. Colorectal adenomatous polyps detected by immunochemical occult blood screening. Hepatogastroenterology. 1998;45:712-6. (Pubitemid 28321045)
15. Levi Z, Rozen P, Hazazi R et al. A quantitative inmunochemical fecal occult blood test for colorectal neoplasia. Ann Intern Med. 2007;146:244-255. (Pubitemid 351650610)
16. Segnan N, Senore C, Andreoni B et al. Comparing attendance and detection rate of colonoscopy with sigmoidoscopy and FIT for colorectal cancer screening. Gastroenterology. 2007;132:2304-12. (Pubitemid 46900821)
17. Peris M, Espinas JA, Munoz L, Navarro M, Binefa G, Borras JM. Lessons learnt from a population-based pilot programme for colorectal cancer screening in Catalonia (Spain). J Med Screen. 2007;14:81-6. (Pubitemid 47067762)
18. Jass JR, Sobin LH. Histological typing of intestinal tumors. 2nd ed. New York: Springer, 1989.
19. Greene FL, Page DL, Fleming ID, Fritz A, Balch DM, Haler DG, et al., editors. AJCC (American Joint Committee on Cancer) Cancer Staging Manual. 6th ed. New York: Springer-Verlag; 2002.
20. Benson VS, Patnick J, Davies AK, Nadel MR, Smith RA, Atkins W. Colorectal cancer screening: a comparisons of 35 initiatives in 17 countries. Int J Cancer.2008;122:1357-67. (Pubitemid 351287237)
21. Málaga A, Salas D, Sala T, Ponce M, Goicoechea M, Andrés M, et al. Programa de cribado de cancer colorrectal de la comunidad valenciana: Resultados de la primera ronda: 2005-2008. Rev Esp Salud Pública.2010;84: 731-43.
22. Brugos-Llamazares V, González de Aledo A, Vada-Sánchez J, Terán-Lantarón A. Resultados del programa de deteccion precoz de cancer colorrectal en Cantabria durante el periodo noviembre de 2008 a marzo de 2010. Rev Esp Salud Pública.2010;84: 757-70.
23. Ascunce N, Salas D, Zubizarreta R, Almazan R, Ibanez J, Ederra M. Cancer screening in Spain. Ann Oncol. 2010;21 Suppl 3:iii43-iii51.
24. Nakama H, Zhang B, Zhang X. Evaluation of the optimum cut-off point in immunochemical occult blood testing in screening for colorectal cancer. Eur J Cancer.2001;37:398-401. (Pubitemid 32182330)
25. Quintero E. ¿Test químico o test inmunológico para la detección de sangre oculta en heces en el cribado del cáncer colorrectal? Gastroenterol Hepatol. 2009; 32 : 565-76.
26. Ferrández A, Navarro M, Díez M, Sopena F, Roncalés P, Polo-Tomas M, et al. Risk factors for advanced lesions undetected at prior colonoscopy: not always poor preparation. Endoscopy.2010;42:1071-6.
27. Li S, Wang H, Hu J, Li N, Liu Y, Wu Z, et al. New immunochemical fecal occult blood test with two-consecuitve stool sample testing is a cost-effective approach for colon cancer screening: results of a prospective multicenter study in Chinese patients. Int J Cancer. 2006;118:3078-83.
28. Parekh M, Fendrick Am, Ladabaum U. As tests evolve and costs of cancer care rise: reappraising stoolbased screening for colorectal neoplasia. Aliment Pharmacol Ther. 2008;27:697-712. (Pubitemid 351406306)
29. Berchi C, Bouvier V, Reaud JM, Launoy G. Costeffectiveness analysis of two strategies for mass screening for colorectal cancer in France. Health Econ.2004;13:227-38. (Pubitemid 38292480)
30. Sala D. Cribado del cáncer colorrectal: fortalezas para avanzar en el cribado en España. Gac Sanit. 2011;25:329-30.